AsianScientist (Sep. 4, 2011) – Australian pharmaceutical company Hatchtech Pty Ltd has completed treatment of subjects for its Phase IIb clinical study to confirm the efficacy of its novel head lice treatment DeOvo™.
Hatchtech’s proprietary product DeOvo™ is a topical formulation of a known metalloprotease inhibitor which targets proteases that are key to biological processes involved in insect hatch and survival.
This study will evaluate the efficacy, safety, and tolerability of two dose levels of a single topical application of DeOvo™ compared to vehicle.
The trial consists of treating 132 healthy subjects with head lice infestation, two years of age and older, in two study centers in the United States, and is expected to be completed in nine months.
“In the US it is estimated that 6-12 million people, mainly children aged 3-12 years, are infested each year with head lice (Pediculus humanus capitis),” said Hatchtech Chairman, Dr. Paul Kelly.
“With the emergence of drug resistant lice and often poor efficacy of existing products, this under-served market represents a substantial commercial opportunity,” he said.
——
Source: Hatchtech Pty. Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
